Seclidemstat clinical trials
Also written SP-2577.
How each study uses seclidemstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the seclidemstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Salarius Pharmaceuticals, LLC (2) · M.D. Anderson Cancer Center (1) · HonorHealth Research Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test seclidemstat.
- Sep 2027Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses seclidemstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Enrolling by invitationPhase 1/2Salarius Pharmaceuticals, LLCNCT05266196Written as Seclidemstat
- Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04734990Written as Seclidemstat
- Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related SarcomasActive, not recruitingPhase 1Salarius Pharmaceuticals, LLCNCT03600649Written as Seclidemstat
- Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic CancersWithdrawnPhase 1HonorHealth Research InstituteNCT04611139Written as SP-2577
Codes
What other systems call seclidemstat · ClinicalTrials.gg INT002071
- UNII (FDA) TYH386V3WJSECLIDEMSTATOne source FDA
- NCI Thesaurus C154328SeclidemstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TYH386V3WJ | SECLIDEMSTAT | One source FDA |
| NCI Thesaurus | C154328 | Seclidemstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.